Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
about
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.Risk-Reducing Strategies for Ovarian Cancer in BRCA Mutation Carriers: A Balancing Act.The effect of hormone therapy on quality of life and breast cancer risk after risk-reducing salpingo-oophorectomy: a systematic reviewPrediction of Cancer Prevention: From Mammogram Screening to Identification of BRCA1/2 Mutation Carriers in Underserved PopulationsPreferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment.Management of women with a hereditary predisposition for breast cancer.How do women at increased breast cancer risk perceive and decide between risks of cancer and risk-reducing treatments? A synthesis of qualitative research.Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance.Bilateral Oophorectomy and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK.Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction.Management of hereditary breast and ovarian cancer.Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.Genetic testing in women with breast cancer: implications for treatment.Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.Predictors of survival for breast cancer patients with a BRCA1 mutation.A new bioinformatics tool to help assess the significance of BRCA1 variants.Risk-Reducing Options for Women with a Hereditary Breast Cancer PredispositionBRCA1/2 testing: therapeutic implications for breast cancer managementPrevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening†
P2860
Q33901361-07A4B583-47CB-486D-BDDA-775D33B8E9AFQ35749439-EA6E4C1E-A02C-4FC0-8C49-A9E860FA08D7Q36210166-263D64C5-8A71-4D43-8079-20ECEFEF4081Q36240959-47498509-9A55-47BE-9942-36A82C0593E9Q36313479-31DE5DD0-F678-4FE4-A435-0FC95A6D0D5EQ36315490-2AA256B1-78B0-4651-980B-9C9DB9B782A6Q36541027-9C587A44-C4E3-45B9-A8B3-F4729CBFA22AQ38669803-B021F713-C03E-4EE7-AC7D-A3A002E0E347Q38844679-9A1E2198-7BE0-4F33-B08D-BBFAC6ADDC30Q39041247-EF61F4D8-1F69-46D9-8803-A72C43AC3383Q40098501-DC842957-AFFA-443E-ADCB-F87A8652827EQ40592257-78DC0698-21DF-4F3A-8E9B-D7899514AFCAQ40732955-BD228315-754D-46B1-9F62-F92DD437D74EQ41517367-EA41BBCE-60F9-4438-A1FB-32FFFFEBF575Q42873665-1509DA92-D33D-4F69-B70A-8014C97FC301Q47399250-3A84E889-A8F0-4E50-ADCD-7A16A48C8F72Q47552886-92BB496A-E601-43AA-8E1A-97C6763D96DDQ47635634-1528AEB6-E268-4DA7-8942-65A213118524Q47884776-21CFB6D8-7025-4868-BA75-DAFF343A36B8Q48110433-6683F16A-6EB8-45AC-8308-7C5EE2A5F685Q48336651-3C0FD950-03CC-4AD5-A75D-3BA4991F0FD5Q49787762-233EB289-442F-4BF3-9F83-8C3A281B34B1Q55639040-6FAEF347-7121-49C7-BAD0-6A6AD8C9EDD9Q57054864-9B96B160-557B-4D40-A1E5-1DB4353402C8Q57110101-8ADBD5E2-F632-4CDE-A16A-AA7822B5C2CEQ59273721-125C9267-4421-474E-BD67-C421B8834C56
P2860
Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Breast cancer risk after salpi ...... e evidence for risk reduction.
@en
type
label
Breast cancer risk after salpi ...... e evidence for risk reduction.
@en
prefLabel
Breast cancer risk after salpi ...... e evidence for risk reduction.
@en
P2093
P2860
P50
P356
P1476
Breast cancer risk after salpi ...... e evidence for risk reduction.
@en
P2093
B A M Heemskerk-Gerritsen
E B Gomez Garcia
F E van Leeuwen
H C van Doorn
H E J Meijers-Heijboer
H F A Vasen
Hereditary Breast and Ovarian Cancer Research Group Netherlands
J M Collée
M A Rookus
P2860
P356
10.1093/JNCI/DJV033
P407
P577
2015-03-18T00:00:00Z